HR 946 · introduced · significant
ORPHAN Cures Act
- healthcare
What this bill does
- This bill excludes orphan drugs from Medicare's drug price negotiation program by not counting time spent as an orphan drug.
- It affects Medicare beneficiaries who use orphan drugs for rare diseases and pharmaceutical companies developing treatments.
- The changes take effect when the Medicare Drug Price Negotiation Program begins in 2026.
Generated by claude-haiku-4-5
Community Threads
Started by Cosponsor
- 01
How might exempting orphan drugs from Medicare price negotiation affect drug development incentives for rare diseases compared to current market conditions?
- 02
What trade-offs exist between preserving pharmaceutical company profits on orphan drugs and keeping medications affordable for Medicare beneficiaries with rare diseases?
- 03
Should orphan drug development timelines be treated differently than other drugs in Medicare negotiations, and what evidence supports that distinction?
Cosponsor writes these to seed civic discussion — they aren't user posts. Sign in to reply.
Sponsor · R-PA-13
John Joyce
Citizen cosponsors
0
In Congress
18/ 435
House Reps cosponsoring
Introduced 2025-02-06
Joining the bill
Shri Thanedar
D-MI-13 · original
Donald G. Davis
D-NC-1 · original
Josh Gottheimer
D-NJ-5 · original
Richard Hudson
R-NC-9 · original
Kevin Hern
R-OK-1 · original
William R. Keating
D-MA-9 · original
Mariannette Miller-Meeks
R-IA-1 · original
Scott H. Peters
D-CA-50 · original
Gus M. Bilirakis
R-FL-12 · original
Dina Titus
D-NV-1
Janelle S. Bynum
D-OR-5
Lloyd Smucker
R-PA-11
+ 6 more
Legislative timeline
2025-02-06 · IntroReferral
Sponsor introductory remarks on measure. (CR H535-536)
2025-02-04 · house · IntroReferral
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2025-02-04 · house · IntroReferral
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2025-02-04 · IntroReferral
Introduced in House
2025-02-04 · IntroReferral
Introduced in House
Citizen comments
Sign in to comment on this bill.
No comments yet — be the first.